Back to search
FDAFDA · Food and drugs·Recall number D-0093-2023

Timolol Maleate Ophthalmic Solution, USP 0.5%, 2.5 mL, Rx Only, Mfg by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Mfg for: Apotex Corp. Weston, FL 33326, NDC 60505-1005-4

Published January 4, 2023 · Recall initiated: December 21, 2022

Summary

FDA records drug Class III recall D-0093-2023, published January 4, 2023 and initiated December 21, 2022. Recalling firm: Apotex Corp.; Status: Terminated; Reported quantity: 22,027 bottles; Lot: Lot# TA4844, Exp 03/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Apotex Corp.
Distributor
USA Nationwide
Lot
Lot# TA4844, Exp 03/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Timolol Maleate Ophthalmic Solution, USP 0.5%, 2.5 mL, Rx Only, Mfg by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Mfg for: Apotex Corp. Weston, FL 33326, NDC 60505-1005-4 recalled?

Yes. FDA published recall D-0093-2023 on January 4, 2023. Reported hazard: Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.

What should I do if I have this product?

Voluntary: Firm initiated · Letter